Bionor Pharma - Acquisition of Solon Eiendom AS completed

Bionor Pharma ASA



Bionor Pharma - Acquisition of Solon Eiendom AS completed

(Oslo, Norway, 15 December 2016) Reference is made to the stock exchange announcement by Bionor Pharma ASA ( "Bionor" or the "Company", ticker "BIONOR") published on 21 November 2016 regarding, inter alia , the entry into of an agreement to acquire the entire share capital of Solon Eiendom AS to be settled wholly by issuance of 6,666,666,666 new shares (the " Consideration Shares ") in the Company (the " Acquisition ") and the stock exchange announcement earlier today regarding a completed extraordinary general meeting of the Company.

The Acquisition has now been completed, save for registration of the share capital increase related to the Consideration Shares in the Norwegian Register of Business Enterprises. Such registration is expected to be made on or about 15 December 2016.

The Consideration Shares will initially be registered on a separate ISIN. The listing of the Consideration Shares is subject to a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company. Following such approval and publishing, the Consideration Shares will be converted to the ordinary ISIN of the Company's shares and be made tradable on Oslo Børs. The prospectus, expected to be published in the middle of January 2017, will contain further details about, inter alia, the Consideration Shares.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
Einar J. Greve
Chairman of the Board, Bionor Pharma ASA
Cell Phone: +47 900 27 766

Simen Thorsen
Chairman of the Board, Solon Eiendom AS
Cell Phone: +47 918 86 886

Unni Hjelmaas
Acting Chief Executive Officer, Bionor Pharma ASA
Cell Phone: +47 915 19 651

About Solon Eiendom
Solon Eiendom is a Norwegian residential real estate development company focusing on the Oslo and Akershus region. Solon Eiendom was established in 2006 by founder Simen Thorsen and investor Tore Aksel Voldberg. The company has since
its incorporation delivered 570 units with a corresponding sales value of close to NOK ~3 billion and sold more than 800 units with a total sales price of more than NOK ~4 billion.

About Bionor
Bionor's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further
advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders.
Bionor is listed on Oslo Børs (OSE: BIONOR). More information about Bionor is available at

Important Information
The release is not for publication or distribution, in whole or in part directly or  indirectly,  in  or  into  Australia,  Canada,  Japan, Hong Kong  or  the United States (including  its territories and possessions, any  state of the United States and the  District  of  Columbia).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States.  Copies of this announcement are not being made and may not be distributed or sent into Australia Canada, Japan, Hong Kong or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company, DNB Markets, Arctic Securities nor SpareBank1 Markets assumes any responsibility in the event there is a violation by any person of such restrictions.

The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bionor Pharma ASA via GlobeNewswire